Medicine guide

Zolgensma

·

  • Prescription status not stated
  • Muscles, joints and bones
Active substance
Onasemnogene abeparvovec
Made by
Novartis Europharm Limited

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Zolgensma is indicated for the treatment of: patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byNovartis Europharm Limited
Active substanceOnasemnogene abeparvovec
Used inMuscles, joints and bones
ClassificationM09AX09 · Muscles, joints and bones
Orphan medicineYes — designated for a rare disease, according to the register
Additional monitoring ▼Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on2020-05-18
Last updated by the regulator2026-08-21
EMA product numberEMEA/H/C/004750

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.